BNP Paribas Financial Markets
DWTX

BNP Paribas Financial Markets’s Dogwood Therapeutics DWTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$4 – 6217
2026
Q1 		$4 Hold
2
– – ﹤0.01% 5785
2025
Q4 		$8 Sell
2
-8
-80% -$47 ﹤0.01% 5698
2025
Q3 		$77 Buy
+10
New +$50 ﹤0.01% 5451

Other funds holding DWTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets's DWTX Position: Q2 2026 in Review

BNP Paribas Financial Markets sold out of Dogwood Therapeutics (DWTX) in Q2 2026, closing a stake of 2 shares — an estimated $4 sold.

BNP Paribas Financial Markets first reported a position in DWTX in Q3 2025 and held it in 3 quarters. The position peaked at $77 in Q3 2025. 15 funds tracked by Wall St. Rank hold DWTX as of Q2 2026.

  • BNP Paribas Financial Markets reported no remaining Dogwood Therapeutics position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 2 Dogwood Therapeutics shares in Q2 2026, an estimated $4.
  • BNP Paribas Financial Markets first reported a position in Dogwood Therapeutics in Q3 2025 and held it in 3 quarters.
  • BNP Paribas Financial Markets's Dogwood Therapeutics position peaked at $77 in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.